Linked Life Data

21054464

Source:http://linkedlifedata.com/resource/pubmed/id/21054464

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2010-11-8
pubmed:abstractText
WHAT IS KNOWN AND OBJECTIVE: Genetic polymorphism of interleukin (IL)-1? and IL-1 receptor antagonist (IL-1r?) are associated with efficacy of acid suppression, whereas cytochrome P (CYP) 2C19 polymorphism influences the metabolism of proton pump inhibitor family. Thus, CYP2C19 and IL-1 polymorphisms may affect the efficacy of H. pylori eradication therapy. We compared the efficacies of omeprazole and rabeprazole on eradication of H. pylori in relation to CYP2C19, IL-1B and IL-1RN genotypes in Chinese people. METHODS: Two hundred and forty Chinese with peptic ulcer disease were randomly assigned to the following regimens: amoxicillin and clarithromycin together with omeprazole (OAC) or rabeprazole (RAC). CYP2C19*2 and *3, IL1B-511, IL1B-31, IL1B+ 3954 and intron 2 of the IL-1RN genotypes were analyzed by polymerase chain reaction-restriction fragment length polymorphism. RESULTS: The intention-to-treat-based cure rate of the OAC regimen was significantly lower than that of the RAC regimen in the CYP2C19 wild-type homozygotes (P?=?0·014). No significant differences in the cure rates were observed among the IL-1RN and the IL-1B genotype groups. WHAT IS NEW AND CONCLUSIONS: The rabeprazole-based triple regimen was better than the omeprazole in Chinese patients with the CYP2C19 extensive metabolizer genotype. The effectiveness of the PPI/AC regimen is unrelated to IL-1B and IL1-RN genetic polymorphism.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1365-2710
pubmed:author
pubmed:copyrightInfo
© 2010 Blackwell Publishing Ltd.
pubmed:issnType
Electronic
pubmed:volume
35
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
713-22
pubmed:meshHeading
pubmed-meshheading:21054464-2-Pyridinylmethylsulfinylbenzimidazoles, pubmed-meshheading:21054464-Adult, pubmed-meshheading:21054464-Aged, pubmed-meshheading:21054464-Anti-Bacterial Agents, pubmed-meshheading:21054464-Anti-Ulcer Agents, pubmed-meshheading:21054464-Aryl Hydrocarbon Hydroxylases, pubmed-meshheading:21054464-Asian Continental Ancestry Group, pubmed-meshheading:21054464-Drug Therapy, Combination, pubmed-meshheading:21054464-Female, pubmed-meshheading:21054464-Genotype, pubmed-meshheading:21054464-Helicobacter Infections, pubmed-meshheading:21054464-Helicobacter pylori, pubmed-meshheading:21054464-Humans, pubmed-meshheading:21054464-Interleukin 1 Receptor Antagonist Protein, pubmed-meshheading:21054464-Interleukin-1beta, pubmed-meshheading:21054464-Male, pubmed-meshheading:21054464-Middle Aged, pubmed-meshheading:21054464-Omeprazole, pubmed-meshheading:21054464-Peptic Ulcer, pubmed-meshheading:21054464-Polymorphism, Single Nucleotide, pubmed-meshheading:21054464-Proton Pumps, pubmed-meshheading:21054464-Young Adult
pubmed:year
2010
pubmed:articleTitle
The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people.
pubmed:affiliation
Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, PR China.
pubmed:publicationType
Journal Article, Randomized Controlled Trial